Showing 31-40 of 106 results for "".
- USPTO Grants Patents to TOOsonix A/S for HIFU Technologies in Dermatologyhttps://practicaldermatology.com/news/uspto-grants-patents-to-toosonix-as-for-hifu-technologies-in-dermatology/2461420/The United States Patent and Trademark Office (USPTO) granted TOOsonix A/S patents regarding its key high-intensity focused ultrasound (HIFU) technologies for dermatology The U.S. patent and already granted patents in Europe and China to complete the first phase of securing intellectual property ri…
- Almirall Finalizes Acquisition of Allergan US Medical Dermatology Portfoliohttps://practicaldermatology.com/news/almirall-finalizes-acquisition-of-allergan-us-medical-dermatology-portfolio/2457600/Almirall, S.A. finalized its acquisition of products from Allergan's Medical Dermatology unit in the US: Aczone (dapsone), Tazorac (tazarotene), Azelex (azelaic acid), and Cordran Tape (flurandrenolide). In addition, sarecycline, a New Chemical Entity (NCE) currently under FDA review for approval i…
- Phase 3 Data for BF-200 ALA Presented at the 14th South Beach Symposiumhttps://practicaldermatology.com/news/phase-3-data-for-bf-200-ala-presented-at-the-14th-south-beach-symposium/2458702/Biofrontera AG’s BF-200 ALA plus red light photodynamic therapy (PDT) shows good efficacy for the treatment of actinic keratoses (AK), according to data presented from three pivotal Phase III trials at the 14th Annual South Beach Symposium. The results were presented in a poster (Poster #118) and w…
- FDA Approves New Combo Drug Plus Device Treatment for AKshttps://practicaldermatology.com/news/fda-approves-new-combo-drug-plus-device-treatment-for-aks/2458568/The FDA approved Biofrontera AG’s combination topical prescription drug Ameluz (BF-200 ALA) and medical device BF-RhodoLED for photodynamic therapy (PDT) treatment of mild-to-moderate actinic keratosis (AK) on the face and scalp. The approval covers lesion-directed as well as field-directed treatme…
- Aclaris Therapeutics Announces Positive Results from Phase IIb Trial of A-101 for the Removal of Seborrheic Keratosishttps://practicaldermatology.com/news/aclaris-therapeutics-announces-positive-results-from-phase-iib-trial-of-a-101-for-the-removal-of-seborrheic-keratosis/2459016/Aclaris Therapeutics, Inc. announced positive results from a Phase IIb clinical trial of the Company’s lead drug, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in clearing multiple seborrheic keratoses (SK). Though the lesions are benign, many patient…
- Biofrontera Inc. Announces FDA Filing of Supplemental New Drug Application for Ameluzhttps://practicaldermatology.com/news/biofrontera-inc-announces-fda-filing-of-supplemental-new-drug-application-for-ameluz/2462237/Biofrontera Inc., a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has issued a "no filing review issues identified" letter regarding the sNDA (supplementary New Drug Application) submitted b…
- Enspectra Health Awarded NIH Grant to Advance Predictive Algorithms for AKshttps://practicaldermatology.com/news/enspectra-health-awarded-nih-grant-to-advance-predictive-algorithms-for-aks/2461874/Enspectra Health scored $2M in grant funding from the National Cancer Institute (NCI) to support research for developing deep learning algorithms to predict which actinic keratosis (AK) lesions, are likely to progress to squamous cell carcinoma (SCC). Enspectra's technology combines reflectance co…
- TOOsonix A/S Rolls Out System ONE-M for Aesthetic Treatmentshttps://practicaldermatology.com/news/toosonix-as-rolls-out-system-one-m-for-aesthetic-treatments/2460449/TOOsonix A/S is launching its CE-marked System ONE-M for color-independent tattoo removal, solar lentigines, spider veins, angiomas, telangiectasia and other aesthetic conditions. System ONE-M is a focused ultrasound device operating at 20 MHz, which creates thermal lesion points in the upper derm…
- Are Skin Diseases More Common Than Previously Held?https://practicaldermatology.com/news/are-skin-diseases-more-common-than-previously-held/2459964/Skin diseases may be more common than previously believed, according to a new study in the Journal of the European Academy of Dermatology and Venereology that estimates the prevalence of skin diseases outside of the typical medical setting. Skin diseases are ranked as the fourth most common cause …
- Almirall to Acquire Allergan's US Medical Dermatology Unithttps://practicaldermatology.com/news/almirall-to-acquire-allergans-us-medical-dermatology-unit/2457661/Almirall is acquiring a portfolio of five products from Allergan’s Medical Dermatology unit in the United States, conditional to the clearance by the relevant authorities. The portfolio includes Aczone® (dapsone), Tazorac® (tazarotene), Azelex® (azelaic acid) and Cordran® Tape (fludroxycortide), as…